Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma

MV. Mateos, J. Bladé, S. Bringhen, EM. Ocio, Y. Efebera, L. Pour, F. Gay, P. Sonneveld, J. Gullbo, PG. Richardson,

. 2020 ; 9 (10) : . [pub] 20200927

Language English Country Switzerland

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc21002051

Grant support
N/A Oncopeptides AB

Despite the availability of new therapies that have led to improved outcomes for patients with multiple myeloma, most patients will eventually relapse. With triplet and even quadruplet combination therapies becoming standard in the first and second line, many patients will have few treatment options after second-line treatment. Melflufen (melphalan flufenamide) is a first-in-class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells. Once inside the tumor cells, melflufen is hydrolyzed by peptidases to release alkylator molecules, which become entrapped. Melflufen showed anti-myeloma activity in myeloma cells that were resistant to bortezomib and the alkylator melphalan. In early phase studies (O-12-M1 and HORIZON [OP-106]), melflufen plus dexamethasone has demonstrated encouraging clinical activity and a manageable safety profile in heavily pretreated patients with relapsed/refractory multiple myeloma, including those with triple-class refractory disease and extramedullary disease. The Phase III OCEAN study (OP-104) is further evaluating melflufen plus dexamethasone in patients with relapsed/refractory multiple myeloma. The safety profile of melflufen is characterized primarily by clinically manageable hematologic adverse events. Melflufen, with its novel mechanism of action, has the potential to provide clinically meaningful benefits to patients with relapsed/refractory multiple myeloma, including those with high unmet needs.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21002051
003      
CZ-PrNML
005      
20210126092703.0
007      
ta
008      
210105s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/jcm9103120 $2 doi
035    __
$a (PubMed)32992506
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Mateos, María-Victoria $u Hospital Clínico Universitario de Salamanca/IBSAL/CIC, 37007 Salamanca, Spain.
245    10
$a Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma. / $c MV. Mateos, J. Bladé, S. Bringhen, EM. Ocio, Y. Efebera, L. Pour, F. Gay, P. Sonneveld, J. Gullbo, PG. Richardson,
520    9_
$a Despite the availability of new therapies that have led to improved outcomes for patients with multiple myeloma, most patients will eventually relapse. With triplet and even quadruplet combination therapies becoming standard in the first and second line, many patients will have few treatment options after second-line treatment. Melflufen (melphalan flufenamide) is a first-in-class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells. Once inside the tumor cells, melflufen is hydrolyzed by peptidases to release alkylator molecules, which become entrapped. Melflufen showed anti-myeloma activity in myeloma cells that were resistant to bortezomib and the alkylator melphalan. In early phase studies (O-12-M1 and HORIZON [OP-106]), melflufen plus dexamethasone has demonstrated encouraging clinical activity and a manageable safety profile in heavily pretreated patients with relapsed/refractory multiple myeloma, including those with triple-class refractory disease and extramedullary disease. The Phase III OCEAN study (OP-104) is further evaluating melflufen plus dexamethasone in patients with relapsed/refractory multiple myeloma. The safety profile of melflufen is characterized primarily by clinically manageable hematologic adverse events. Melflufen, with its novel mechanism of action, has the potential to provide clinically meaningful benefits to patients with relapsed/refractory multiple myeloma, including those with high unmet needs.
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Bladé, Joan $u Hematology Department, Institut d'Investigacions Biomèdiques August Pi I Sunyer, Hospital Clinic, 08036 Barcelona, Spain.
700    1_
$a Bringhen, Sara $u Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, 10126 Torino, Italy.
700    1_
$a Ocio, Enrique M $u University Hospital Marqués de Valdecilla (IDIVAL), University of Cantabria, 39008 Santander, Spain.
700    1_
$a Efebera, Yvonne $u Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
700    1_
$a Pour, Luděk $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, 62500 Brno, Czech Republic.
700    1_
$a Gay, Francesca $u Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, 10126 Torino, Italy.
700    1_
$a Sonneveld, Pieter $u Erasmus MC Cancer Institute, 3075 EA Rotterdam, The Netherlands.
700    1_
$a Gullbo, Joachim $u Department of Medical Sciences, Division of Clinical Pharmacology, Uppsala University, 751 85 Uppsala, Sweden.
700    1_
$a Richardson, Paul G $u Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
773    0_
$w MED00195462 $t Journal of clinical medicine $x 2077-0383 $g Roč. 9, č. 10 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32992506 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210126092659 $b ABA008
999    __
$a ind $b bmc $g 1614131 $s 1122335
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 9 $c 10 $e 20200927 $i 2077-0383 $m Journal of clinical medicine $n J Clin Med $x MED00195462
GRA    __
$a N/A $p Oncopeptides AB
LZP    __
$a Pubmed-20210105

Find record

Citation metrics

Archiving options